FAQ
Frequently Asked Questions
The European market for medical imaging AI solutions is projected to reach €2 billion by 2025, with a significant portion dedicated to chest imaging. Finland, with its strong healthcare system and openness to innovation, represents an initial market of approximately €20-30 million annually.
RespiroAI focuses on a broad range of lung pathologies, not just specific diseases. Our AI is trained on real datasets, ensuring optimal performance within our target market. Additionally, we prioritize seamless integration into existing hospital workflows for ease of adoption.
Our vision is for RespiroAI to become a comprehensive AI-powered diagnostic platform for chest imaging. We’ll expand our analysis beyond X-rays to include CT scans and other modalities. Ultimately, we aim to empower healthcare providers with an AI-assisted workflow that supports multiple pathologies for improved patient outcomes.
Our internal studies show sensitivity exceeding 90% and specificity of 85% in detecting various lung abnormalities. We’re collaborating with Helsinki University Hospital (HUS) on an independent validation study and are actively planning a multi-center clinical trial.
We utilize state-of-the-art deep learning models, specifically convolutional neural networks optimized for medical image analysis. Our AI leverages techniques like transfer learning and data augmentation for robust performance.
Security and privacy are paramount. We’re fully GDPR compliant, and all patient data is anonymized and encrypted. We are pursuing ISO 27001 certification to demonstrate our commitment to data security
Yes! We have two successful pilot programs underway in the Helsinki region with positive initial feedback. We’ve also secured two pre-sales agreements with European healthcare providers, signifying strong interest upon regulatory approval.